Vanda Pharmaceuticals PE ratio VNDA

Share price divided by earnings per share over the last twelve months, since 2015.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 97.6×; May 2024
8-year median: 34.4×
8-year range: 15.4× to 129×
Peer median: 11.3×

Vanda Pharmaceuticals has no meaningful PE ratio today: it lost $4.63 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in May 2024, at 97.6×.

On the days it had one over the last 8 years, its median was 34.4×, from 15.4× in Oct 2023 to 129× in Jan 2019.

PE ratio over time

median 34.4×

The dashed line is the 8-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	97.6×	17.3×	102×
2023	20.1×	15.4×	63.9×
2022	61.6×	17.1×	90.9×
2021	25.7×	25.7×	43.5×
2020	36.5×	29.7×	38.4×
2019	26.7×	24.4×	129×
2018	107×	99.2×	115×
2017	n/m a value too high to mean anything
2016	7.3×	7.0×	7.7×
2015	7.9×	7.3×	33.2×

Against its peers

Companies in Drug Manufacturers - General nearest Vanda Pharmaceuticals' size, closest first, today.

Company	PE ratio
VNDAVanda Pharmaceuticals	n/m
NATRNatures Sunshine Products	12.0×
ARVNArvinas	45.6×
PBYIPuma Biotechnology	21.2×
IRWDIronwood Pharmaceuticals	4.5×
ZVRAZevra Therapeutics	10.5×
CRMDCorMedix	3.7×
COLLCollegium Pharmaceutical	18.5×
LFVNLifevantage	14.7×
ABUSArbutus Biopharma	5.4×
SPROSpero Therapeutics	10.1×
Peer median	11.3×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Vanda Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.